Eclipsebio develops first-in-class technologies and analyses to support the successful development of RNA-based and RNA-targeting therapies. With the company’s extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, they provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. The company offers its solutions as end-to-end partnerships to make the RNA medicines of tomorrow achievable today.